title: Management of acute and chronic HCV infection in persons with HIV coinfection.
abstract: Due to shared routes of transmission, acute and chronic infection with hepatitis C virus is common among persons living with HIV infection in many regions of the world. In the era of effective antiretroviral therapy, acute HCV infection has been increasingly recognized in HIV-infected persons, particularly men who have sex with men, and liver disease, including hepatocellular carcinoma, has emerged as a leading cause of morbidity and mortality in those with chronic HCV infection, particularly older adults with long-standing coinfection. Over the past decade, the foundation for the management of acute and chronic HCV infection has been interferon alfa. However, due the high burden of treatment-related side effects and low likelihood of sustained virologic response, the impact of treatment with peginterferon/ribavirin on the burden of HCV disease in has been limited. However, the anticipated availability of safe, tolerable and highly efficacious interferon-free, oral HCV direct-acting antiviral combination therapies promise to dramatically change the management of acute and chronic HCV infection in HIV-infected persons. Preliminary data from studies of such oral DAA regimens in HIV/HCV coinfected patients suggest that coinfection with HIV will not impair HCV cure with these regimens. Indeed, in the coming era of high effective oral HCV DAA treatments, the only special feature concerning treatment of acute and chronic HCV infection in HIV-infected patients may be drug interactions between the antiretroviral drugs for HIV infection and direct-acting antiviral drugs for HCV infection.
authors.affiliation: Johns Hopkins University, School of Medicine, Baltimore, MD, United States. Electronic address: msulkowski@jhmi.edu.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Sulkowski
mesh_terms: D000208:Acute Disease; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D060085:Coinfection / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D015897:Comorbidity; D019468:Disease Management; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D006801:Humans; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D000998:Antiviral Agents
keywords: Direct-acting antivirals; HCV; HIV; Interferon; NS5A inhibitors; Polymerase inhibitors; Protease inhibitors